PER 4.29% 6.7¢ percheron therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-14

  1. 4,336 Posts.
    lightbulb Created with Sketch. 2023
    One of the better reports seen from ANP. I am liking this investigation into cd49 ailments. Multiple kicks at goal from the one drug

    Still risk, but incredible value at this market cap.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.